Skip to main content
SpringerLink
Log in

Use of Enoxaparin in Patients with Chronic Kidney Disease

Safety Considerations

  • Commentary
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30(5): 579–89

    Article  PubMed  CAS  Google Scholar 

  2. United States Renal Data Systems (USRDS). 2006 annual data report: atlas of chronic kidney disease and end stage renal disease in the United States. Chapter 6: Morbidity and mortality. Am J Kidney Dis 2007; 49 (1 Suppl.): S130–46994

    Google Scholar 

  3. Antman EM, McCabe CH, Gurfinkle EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/ non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100(15): 1593–601

    Article  PubMed  CAS  Google Scholar 

  4. Cohen M, Demers C, Gurfinkle EP, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol 1998; 82(5B): 19L–24L

    Article  PubMed  CAS  Google Scholar 

  5. Buckley MM, Sorkin EM. Enoxaparin: a review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992; 44: 465–97

    Article  PubMed  CAS  Google Scholar 

  6. Noble S, Spencer CM. Enoxaparin: a review of its clinical potential in the management of coronary artery disease. Drugs 1998; 56: 259–72

    Article  PubMed  CAS  Google Scholar 

  7. Chow SL, Zammit K, West K, et al. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003; 43: 586–90

    PubMed  CAS  Google Scholar 

  8. Lovenox® (enoxaparin sodium) [package insert]. Bridgewater (NJ): Sanofi-Aventis Pharmaceuticals, 2007 Jun

  9. Brophy DF, Carr ME, Martin EJ, et al. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamics in patients receiving dialysis therapies. J Clin Pharmacol 2006; 465: 887–94

    Article  Google Scholar 

  10. Brophy DF, Martin EJ, Gehr TWB, et al. Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. J Thromb Haemost 2006; 4: 372–6

    Article  PubMed  CAS  Google Scholar 

  11. Gheno G, Cinetto L, Savarino C, et al. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur J Clin Pharmacol 2003; 59: 373–7

    Article  PubMed  CAS  Google Scholar 

  12. Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673–84

    PubMed  CAS  Google Scholar 

  13. Spinier SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146: 33–41

    Article  Google Scholar 

  14. Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004; 125: 856–63

    Article  PubMed  CAS  Google Scholar 

  15. Collet JP, Montalescot G, Fine E, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003; 41: 8–14

    Article  PubMed  CAS  Google Scholar 

  16. Collet JP, Montalescot G, Choussat R, et al. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 2001; 80: 81–2

    Article  PubMed  CAS  Google Scholar 

  17. Hulot JS, Montalescot G, Lechat P, et al. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005; 77: 542–52

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have no conflicts of interest that are directly relevant to the content of this commentary. No sources of funding were used to assist in the preparation of this commentary.

Author information

Authors and Affiliations

  1. Division of Pharmacy, Virginia Commonwealth University/Medical College of Virginia Campus, P.O. Box 980533, Richmond, Virginia, 23298-0533, USA

    Donald F. Brophy (Associate Professor of Pharmacy and Medicine)

  2. Division of Nephrology, Virginia Commonwealth University/Medical College of Virginia Campus, Richmond, Virginia, USA

    Donald F. Brophy (Associate Professor of Pharmacy and Medicine) & Domenic A. Sica

  3. Section of Clinical Pharmacology and Hypertension, Virginia Commonwealth University/Medical College of Virginia Campus, Richmond, Virginia, USA

    Domenic A. Sica

Authors
  1. Donald F. Brophy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Domenic A. Sica
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donald F. Brophy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brophy, D.F., Sica, D.A. Use of Enoxaparin in Patients with Chronic Kidney Disease. Drug-Safety 30, 991–994 (2007). https://doi.org/10.2165/00002018-200730110-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200730110-00001

Search

Navigation